Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118482 · ClinicalTrials.gov registry record · Phase 4
Clinical Trial for the Prevention of Vasovagal Syncope
A Phase 4 study, sponsored by University of Calgary.
- Completed
- Registry status
- Phase 4
- Development phase
- 213
- Enrollment target
NCT00118482 is a Phase 4 study that has completed, run by University of Calgary. The registered enrollment target is 213 participants.
The verdict
NCT00118482, a Phase 4 study, has completed, sponsored by University of Calgary.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 213 participants
- Enrollment target
Study Summary
The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
Interventions
- DRUG fludrocortisone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118482
The ClinicalTrials.gov registry entry for NCT00118482 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Calgary, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fludrocortisone acetate is the first listed.
NCT00118482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118482 about?
NCT00118482 is a clinical study titled "Clinical Trial for the Prevention of Vasovagal Syncope". The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people f...
What is the current status of trial NCT00118482?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 213 participants. The study started on 2005-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00118482?
The interventions under investigation include: fludrocortisone acetate (DRUG).
Who is sponsoring clinical trial NCT00118482?
This trial is sponsored by University of Calgary, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.